On April 28, 2020, we released our seventh webinar, Alternative Endpoints. This topic was presented by Dr. Kert Viele, Director and Senior Statistical Scientist at Berry Consultants, LLC.
Clinical trials generate large amounts of data, which we summarize through trial endpoints. Ideally, these endpoints are clinically meaningful and sensitive to differences in treatment. Unfortunately, often the most meaningful endpoints, such as mortality, can be less sensitive while sensitive endpoints, such as biomarkers, can lack clear clinical meaning. In this talk Dr. Kert Viele will discuss the value of different endpoints and discuss alternatives which attempt to retain clinical meaning while allowing more sensitivity to treatment effects, and hence more power and/or smaller sample sizes.